User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Apixaban versus warfarin in patients with atrial fibrillation.

Primary tabs

Granger, Christopher B Alexander, John H McMurray, John J V Lopes, Renato D Hylek, Elaine M Deceuninck, Olivier [UCL]

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2011
Language Anglais
Journal information "New England Journal of Medicine" - Vol. 365, no.11, p. 981-92 (2011)
Peer reviewed yes
Publisher Massachusetts Medical Society ((United States) [S.l.])
issn 0028-4793
e-issn 1533-4406
Publication status Publié
Affiliation UCL - (MGD) Service de cardiologie
MESH Subject Aged ; International Normalized Ratio ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Pyrazoles ; Pyridones ; Stroke ; Thromboembolism ; Treatment Outcome ; Warfarin ; Anticoagulants ; Atrial Fibrillation ; Double-Blind Method ; Factor Xa ; Female ; Follow-Up Studies ; Hemorrhage ; Humans
Links
Bibliographic reference Granger, Christopher B ; Alexander, John H ; McMurray, John J V ; Lopes, Renato D ; Hylek, Elaine M ; et. al. Apixaban versus warfarin in patients with atrial fibrillation.. In: New England Journal of Medicine, Vol. 365, no.11, p. 981-92 (2011)
Permanent URL http://hdl.handle.net/2078.1/126924